• Renalytix is granted a Clinical Laboratory Permit for KidneyIntelX from the NYS Department of Health, following an extensive review by a panel of Department of Health scientists and external reviewers of the analytical and clinical validation results.
  • Renalytix announces partnership with University of Michigan to extend its KidneyIntelX platform to an expanded population of CKD patients or patients at risk for developing CKD.


  • Renalytix proposes dual-listing on NASDAQ.